Risk of Vestibular Schwannoma in patients on hormone therapy.

Hormone therapy linked to higher risk of Vestibular Schwannoma.

Link between Vestibular Schwannoma and hormone therapy needs more study.

Compare the risk of developing Vestibular schwannoma in patients prescribed Hormone Therapy (HT).

We performed a systematic review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA), the search was conducted in English, and we included all the studies that met the following criteria: (a) Participants who presented with VS; (b) Patients prescribed Hormone Replacement Therapy (HRT); (c) Prospective, retrospective or case-control study.

Of the 146 articles, four met the inclusion criteria and were included in the systematic review and meta-analysis. Two studies documented an increased relative risk of Vestibular schwannoma in patients that had ever used hormone replacement therapy, another study found an incidence rate 2.2 times higher than the expected incidence rate and the other study indicated a 10% increased odds of the Vestibular Schwannoma in patients who have ever used hormone replacement therapy.

The use of hormone replacement therapy was associated with an increased relative risk of Vestibular Schwannoma but also demonstrated a lack of a definitive association.

Level 1.

Estrogen

Progestin

Vestibular Schwannoma

Hormone therapy

Meta-analysis

© 2025 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.